フェーズ3 GO-ALIVE試験における活動性成人強直性脊椎炎の倦怠感に対するゴリムマブ静脈注射の影響と臨床的反応性との関連
Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y
Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.